{{Infobox company
| name             = Protalix BioTherapeutics Inc.
| logo             = [[File:Protalix logo.jpg]]
| caption          = Protalix logo
| type             = [[Public company|Public]]
| traded_as        = {{AMEX|PLX}}<br />{{TASE|PLX}}
| fate             =
| successor        =
| foundation       = {{Start date|1993}}
| founder          = Yoseph Shaaltiel
| defunct          = <!-- {{End date|YYYY|MM|DD}} -->
| location_city    = [[Carmiel]]
| location_country = [[Israel]]
| location         =
| locations        =
| area_served      =
| key_people       = David Aviezer, CEO
| industry         = [[Biotechnology]]
| products         = [[Elelyso]]
| services         =
| revenue          =
| operating_income =
| net_income       =
| assets           =
| equity           =
| owner            =
| num_employees    =
| parent           =
| divisions        =
| subsid           =
| homepage         = {{Url|www.protalix.com}}
| footnotes        = <ref>[http://online.wsj.com/article/BT-CO-20111206-710412.html FDA Extends Review Of Protalix's Rare-Disease Drug]</ref>
| intl             =
}}

'''Protalix BioTherapeutics''' is an [[Israel]]i pharmaceutical company whose plant-based enzyme, [[taliglucerase alfa]], has been approved by the U.S. Food and Drug Administration for the treatment of [[Gaucher disease]].

==Corporate history==
Protalix BioTherapeutics was established in 1993.<ref>[http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-faq_pf#40212 Investor FAQ]</ref> It was founded by Yoseph Shaaltiel, who received his Ph.D. in [[Plant biochemistry|Plant Biochemistry]] from the [[Weizmann Institute]] in Israel and served in the Biology Department of the [[Israel Defense Forces]]' Biological and Chemical Center.<ref>{{cite web|title=Yoseph Shaaltiel Ph.D.|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=941525&ticker=PLX:US|work=[[Bloomberg Businessweek]]|accessdate=3 May 2012}}</ref> One of the earliest and largest investors in the company was [[Phillip Frost]].<ref>{{cite news|last=Tsipori|first=Tali|title=With Protalix worth $801m, chairman Frost cuts stake|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000617866&fid=1725|accessdate=4 May 2012|newspaper=[[Globes]]|date=24 January 2011}}</ref>

In its early days Protalix operated out of a warehouse in the town of [[Qiryat Shemona]] in northern Israel.<ref>{{cite news|last=Korenfeld|first=Tomer|title='מי שלא מאמין שיצליח, אין לו מה לחפש במקצוע הזה. נתחיל למכור את התרופה למחלת הגושה כבר בתוך מספר שבועות'|url=http://www.bizportal.co.il/shukhahon/biznews02.shtml?mid=317096&p_id=&maavar=1|accessdate=3 May 2012|newspaper=Bizportal|date=2 ay 2012|language=Hebrew|trans_title='Whoever doesn't believe he'll succeed has nothing to look for in this field. We'll begin selling the treatment for Gaucher's disease within a few weeks'|quote=בעקבות האישור, מנכ"ל פרוטליקס דוד אביעזר התראיין ל-Bizportal על הדרך שעברה חברת הביומד הקטנה שהחלה במוסך בקרית שמונה ועד האישור המיוחל.}}</ref> Protalix entered into a partnership agreement with [[Teva Pharmaceutical Industries]] in 2006 for the development of two proteins<ref>{{cite journal|title=Teva, Protalix collaborate on two biopharmaceuticals|journal=Drug Discovery News|year=2006|month=November|accessdate=3 May 2012|publisher=Old River Publications|location=[[Rocky River, Ohio]]|quote=Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. have signed a collaboration and licensing agree­ment for the development of two proteins, using Protalix’s plant cell culture platform.}}</ref> and in 2009 signed a collaboration agreement with [[Pfizer]] for the development and commercialization of its taliglucerase alfa treatment.<ref>{{cite news|last=Loftus|first=Peter|title=Pfizer-Protalix Deal Bolsters Competition For Genzyme|url=http://online.wsj.com/article/SB10001424052748704107104574569530771644554.html|accessdate=3 May 2012|newspaper=[[The Wall Street Journal]]|date=2 December 2009}}</ref> Also in 2009, Protalix reported that [[Frost & Sullivan]] presented the company with its 2009 European Orphan Diseases
Market Product Innovation of the Year Award.<ref>{{cite news|title=Frost & Sullivan Presents Protalix Biotherapeutics with its 2009 European Orphan Diseases Market Product Innovation of the Year Award|url=http://www.bloomberg.com/apps/news?pid=conewsstory&tkr=PBD:GR&sid=aX77eP00CGCg|accessdate=4 May 2012|newspaper=[[Bloomberg L.P.{{!}}Bloomberg]]|date=4 June 2009|agency=[[Business Wire]]}}</ref> In 2011 Protalix announced that the U.S. Food and Drug Administration had approved the company's manufacturing facility in [[Carmiel]].<ref>{{cite news|last=Gorodisher|first=Jonathan|title=פרוטליקס חושפת: ה-FDA ביקר כבר במפעל בכרמיאל 'מעלה את הסיכוי לאישור'|url=http://www.bizportal.co.il/shukhahon/biznews02.shtml?mid=264113|accessdate=3 May 2012|newspaper=Bizportal|date=24 February 2011|language=Hebrew|trans_title=Protalix reveals: the FDA already visited the plant in Karmiel 'increases the probability of approval'|quote=מפעל הייצור של חברת פרוטליקס בכרמיאל אושר על ידי מנהל המזון והתרופות האמריקני (FDA) בביקורת שנערכה החודש, כך עולה מהדו"חות השנתיים שפרסמה חברת הביומד הבוקר (ה').}}</ref>

Protalix initially became a public company through a [[reverse merger]] process with Orthodontix, a company which was at the time traded [[OTCBB|"over the counter"]] on the [[NASDAQ]].<ref name="PlantBio">{{cite book|url=http://books.google.com/books?id=jUVlxEkjy7oC&pg=PA465&dq=protalix&hl=en&sa=X&ei=hZAUT8_DKYinhAeumuiGAg&ved=0CDAQ6AEwAA#v=onepage&q=protalix&f=false|title=Plant Biotechnology and Agriculture: Prospects for the 21st Century|first=Arie|last=Altman|pages=465–466|ISBN=0-12-381466-9|publisher=[[Academic Press]]|year=2011}}</ref> This merger was completed on December 31, 2006, and is notable as one of the largest reverse mergers executed, valuing the joint entity at almost $1 Billion.<ref>{{cite book|url=http://books.google.com/books?id=UJP9wzee4jwC&pg=PA286&dq=protalix&hl=en&sa=X&ei=hZAUT8_DKYinhAeumuiGAg&ved=0CEQQ6AEwAw#v=onepage&q=protalix&f=false|title=The Issuer's Guide to PIPEs: New Markets, Deal Structures, and Global Opportunities for Private Investments in Public Equity|first=Steven|last=Dresner|page=286|ISBN=0-470-88349-9|year=2010|publisher=[[John Wiley & Sons]]}}</ref> It subsequently applied for a listing on the AMEX, and sold 10 million shares in a public offering.

==Products==
Protalix uses cultured plant cells to manufacture bio pharmaceuticals. As of 2012, it has developed two such products, the second of which continues to undergo clinical trials:
* Taliglucerase alfa – a recombinant [[glucocerebrosidase]] enzyme produced from [[Genetically modified plant|transgenic]] carrot cell cultures.<ref>{{cite book|url=http://books.google.com/books?id=biGwUBUpTZMC&pg=PA60&dq=protalix&hl=en&sa=X&ei=hZAUT8_DKYinhAeumuiGAg&ved=0CEkQ6AEwBA#v=onepage&q=protalix&f=false|title=Molecular Farming in Plants: Recent Advances and Future Prospects|first=Aiming |last=Wang|page=60|ISBN=94-007-2216-8|year=2011|publisher=[[Springer Science+Business Media|Springer]]}}</ref> Known also as ''Elelyso'', taliglucerase won approval from the [[U.S. Food and Drug Administration]] in May 2012 as an [[orphan drug]] for the treatment of Type 1 [[Gaucher's disease]].<ref>{{cite news|last=Yukhananov|first=Anna|title=U.S. FDA approves Pfizer/Protalix drug for Gaucher|url=http://www.chicagotribune.com/health/sns-rt-us-fda-gaucherbre8401jz-20120501,0,5155428.story|accessdate=2 May 2012|newspaper=[[Chicago Tribune]]|date=1 May 2012|agency=[[Reuters]]}}</ref>
* PRX-105 – a recombinant human [[Acetylcholinesterase]], also produced from transgenic carrot, cells<ref name="PlantBio"/> which can be used as a counter-measure against [[nerve agents]] attack. PRX-105 completed Phase I clinical trails.<ref name=israel21c>{{cite news|title=Israeli agent fights the nerve gas threat|url=http://israel21c.org/health/israeli-agent-fights-the-nerve-gas-threat/|accessdate=4 May 2012|newspaper=Israel21c|date=8 August 2010}}</ref>

== See also ==
*[[List of companies of Israel]]
*[[TA BlueTech-50 Index]]
*[[Velaglucerase alfa]]

== References ==
{{Reflist|2}}

== External links ==
{{Finance links
| name = Protalix BioTherapeutics Inc.
| symbol = PLX
| sec_cik = 1006281
| hoovers = 
}}

[[Category:Biotechnology companies of Israel]]
[[Category:Pharmaceutical companies of Israel]]
[[Category:Companies established in 1993]]
[[Category:Companies listed on TASE]]
[[Category:Companies listed on the American Stock Exchange]]